Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
百时美施贵宝(US:BMY) Businesswire·2025-10-10 18:59公司战略与交易 - 百时美施贵宝通过收购Orbital Therapeutics来加强并多元化其细胞治疗产品组合 [1] 行业动态 - 细胞治疗领域出现重要并购交易 表明行业整合与资产强化趋势 [1]